CA2473158C - Treatment of rheumatoid arthritis using imatinib - Google Patents

Treatment of rheumatoid arthritis using imatinib Download PDF

Info

Publication number
CA2473158C
CA2473158C CA2473158A CA2473158A CA2473158C CA 2473158 C CA2473158 C CA 2473158C CA 2473158 A CA2473158 A CA 2473158A CA 2473158 A CA2473158 A CA 2473158A CA 2473158 C CA2473158 C CA 2473158C
Authority
CA
Canada
Prior art keywords
pharmaceutical composition
component
rheumatoid arthritis
present
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2473158A
Other languages
English (en)
French (fr)
Other versions
CA2473158A1 (en
Inventor
Heikki Joensuu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Helsinki University Hospital
Original Assignee
Helsinki University Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helsinki University Hospital filed Critical Helsinki University Hospital
Publication of CA2473158A1 publication Critical patent/CA2473158A1/en
Application granted granted Critical
Publication of CA2473158C publication Critical patent/CA2473158C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
  • Liquid Crystal Substances (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA2473158A 2002-01-28 2003-01-27 Treatment of rheumatoid arthritis using imatinib Expired - Fee Related CA2473158C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0201882.8 2002-01-28
GBGB0201882.8A GB0201882D0 (en) 2002-01-28 2002-01-28 Organic compounds
PCT/EP2003/000802 WO2003063844A2 (en) 2002-01-28 2003-01-27 Treatment of rheumatoid arthritis using imatinie

Publications (2)

Publication Number Publication Date
CA2473158A1 CA2473158A1 (en) 2003-08-07
CA2473158C true CA2473158C (en) 2013-06-11

Family

ID=9929858

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2473158A Expired - Fee Related CA2473158C (en) 2002-01-28 2003-01-27 Treatment of rheumatoid arthritis using imatinib

Country Status (22)

Country Link
US (2) US20060264443A1 (enExample)
EP (1) EP1471916B1 (enExample)
JP (1) JP4398731B2 (enExample)
KR (1) KR101030416B1 (enExample)
CN (1) CN1646130A (enExample)
AT (1) ATE399555T1 (enExample)
BR (1) BR0307286A (enExample)
CA (1) CA2473158C (enExample)
DE (1) DE60321888D1 (enExample)
DK (1) DK1471916T3 (enExample)
ES (1) ES2309299T3 (enExample)
GB (1) GB0201882D0 (enExample)
IL (1) IL162983A (enExample)
MX (1) MXPA04007309A (enExample)
NO (1) NO328255B1 (enExample)
NZ (1) NZ534137A (enExample)
PL (1) PL212137B1 (enExample)
PT (1) PT1471916E (enExample)
RU (1) RU2322238C2 (enExample)
SI (1) SI1471916T1 (enExample)
WO (1) WO2003063844A2 (enExample)
ZA (1) ZA200405323B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2479257A1 (en) * 2002-03-21 2003-10-02 Dana-Farber Cancer Institute, Inc. Inhibition of cell death responses induced by oxidative stress
US20050130986A1 (en) * 2003-11-21 2005-06-16 Eklund Kari K. Treatment of spondylarthropathies
US20080248022A1 (en) * 2004-09-08 2008-10-09 Immunaid Pty Ltd Therapeutic Strategy for Treating Autoimmune and Degenerative Diseases
JP2010500283A (ja) * 2006-05-31 2010-01-07 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー チロシンキナーゼ阻害剤を用いて炎症性疾患を治療する方法
CN102512421B (zh) * 2011-10-28 2013-11-06 中国科学院广州生物医药与健康研究院 哌嗪酰胺类化合物在制药中的应用
KR101386697B1 (ko) 2012-06-18 2014-04-18 아주대학교산학협력단 이매티닙 또는 이의 약학적으로 허용되는 염을 유효성분으로 포함하는 혈관 투과성 관련 질환의 치료 또는 예방용 조성물
RU2580656C1 (ru) * 2014-11-20 2016-04-10 Закрытое Акционерное Общество "БИОКОМ" Твердая лекарственная форма гидроксихлорохина немедленного высвобождения и способ ее получения
US20210380685A1 (en) * 2018-10-18 2021-12-09 Sinomab Bioscience Limited Methods of Treating Rheumatoid Arthritis
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4316884A (en) * 1979-01-25 1982-02-23 Adria Laboratories, Inc. Sustained release pharmaceutical formulation
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
US5792476A (en) * 1996-12-19 1998-08-11 Abigo Medical Ab Sustained release glucocorticoid pharmaceutical composition
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
TW550258B (en) * 1999-05-31 2003-09-01 Hoffmann La Roche 4-phenyl-pyrimidine derivatives
CO5200760A1 (es) * 1999-06-16 2002-09-27 Smithkline Beecham Corp Antagonistas del receptor de la il-8 ceptor il-8
GB0108606D0 (en) * 2001-04-05 2001-05-23 Novartis Ag Organic compounds
EP1414500A4 (en) * 2001-04-16 2005-01-12 Uab Research Foundation Akt and regulation of ra synovial fibroblast apoptosis
AU2002342335B2 (en) * 2001-05-16 2006-02-02 Novartis Ag Combination comprising N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent
ATE330608T1 (de) * 2001-06-29 2006-07-15 Ab Science Die verwendung von n-phenyl-2-pyrimidine-amine derivaten zur behandlung von entzündlichen erkrankungen

Also Published As

Publication number Publication date
ATE399555T1 (de) 2008-07-15
HK1072192A1 (en) 2005-08-19
EP1471916B1 (en) 2008-07-02
US20090131382A1 (en) 2009-05-21
NO20043585L (no) 2004-10-21
NO328255B1 (no) 2010-01-18
PL212137B1 (pl) 2012-08-31
PT1471916E (pt) 2008-10-03
WO2003063844A3 (en) 2004-04-01
ES2309299T3 (es) 2008-12-16
KR20040086301A (ko) 2004-10-08
WO2003063844A2 (en) 2003-08-07
JP4398731B2 (ja) 2010-01-13
PL370264A1 (en) 2005-05-16
NZ534137A (en) 2007-03-30
IL162983A (en) 2010-06-16
JP2005526022A (ja) 2005-09-02
ZA200405323B (en) 2005-08-31
RU2322238C2 (ru) 2008-04-20
MXPA04007309A (es) 2005-09-12
EP1471916A2 (en) 2004-11-03
US20060264443A1 (en) 2006-11-23
DE60321888D1 (enExample) 2008-08-14
CN1646130A (zh) 2005-07-27
DK1471916T3 (da) 2008-10-20
CA2473158A1 (en) 2003-08-07
RU2004126447A (ru) 2005-07-10
SI1471916T1 (sl) 2008-12-31
GB0201882D0 (en) 2002-03-13
BR0307286A (pt) 2004-12-28
KR101030416B1 (ko) 2011-04-20

Similar Documents

Publication Publication Date Title
US20090131382A1 (en) Treatment of rheumatoid arthritis using imatinib
AU2010341000B2 (en) Combination preparations comprising a cytokine antagonist and corticosteroid
KR100824491B1 (ko) 면역염증 질환의 치료를 위한 조합
JP2022531906A (ja) 関節炎性疾患の組み合わせ療法
RU2016109944A (ru) Антитела, нейтрализующие gm-csf, для применения в лечении ревматоидного артрита или в качестве анальгетиков
CA3217278A1 (en) Methods of treatment of autoimmune disorders using ilt7 binding proteins
JP2005526022A5 (ja) 関節リウマチの処置
AU2007201056B2 (en) Treatment of rheumatoid arthritis using imatinib
AU2003206783A1 (en) Treatment of rheumatoid arthritis using imatinie
US20050130986A1 (en) Treatment of spondylarthropathies
HK1072192B (en) Treatment of rheumatoid arthritis using imatinib
JPH05310573A (ja) リウマチ治療薬
US20120142605A1 (en) Methods of treating psoriasis
US20230000822A1 (en) A combination of a btk inhibitor and abatacept for the treatment of rheumatoid arthritis
CA3162956A1 (en) Use of masitinib for the treatment of eosinophilic asthma
US11648252B2 (en) Methotrexate for use as a medicament
HK40113661A (en) Cd40l-specific tn3-derived scaffolds for use in the treatment and prevention of rheumatoid arthritis
JP2005531622A5 (enExample)

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20160127